Bioorganic and Medicinal Chemistry Letters p. 526 - 531 (2014)
Update date:2022-08-03
Topics:
Sun, Shaoyi
Zhang, Zaihui
Raina, Vandna
Pokrovskaia, Natalia
Hou, Duanjie
Namdari, Rostam
Khakh, Kuldip
Ratkay, Leslie G.
McLaren, David G.
Mork, Monica
Fu, Jianmin
Ferreira, Suzie
Hubbard, Brian
Winther, Michael D.
Dales, Natalie
We discovered a series of novel and potent thiazolylpyridinone-based SCD1 inhibitors based on a 2-aminothiazole HTS hit by replacing the amide bond with a pyridinone moiety. Compound 19 demonstrated good potency against SCD1 in vitro and in vivo. The mouse liver microsomal SCD1 in vitro potency for 19 was improved by more than 240-fold compared to the original HTS hit. Furthermore, 19 demonstrated a dose-dependent reduction of plasma desaturation index with an ED50 of 6.3 mg/kg. Compound 19 demonstrated high liver to plasma and liver to eyelid exposures, indicating preferential liver distribution. The preliminary toxicology study with compound 19 did not demonstrate adverse effects related to SCD1 inhibition, suggesting a wide safety margin with respect to other known SCD1 inhibitors with wider distribution profiles.
View MoreNantong Auxin Electronic Technology Co., LTD
Contact:86-513-88760026
Address:NO.5-1, Aoxin Road, Haian Hi-tech Development Zone, Jiangsu Province, China
Contact:+86-25-52346955
Address:199,JIANYE ROAD,NANJING,CHINA
Jiangsu Cale New Material Co.ltd
Contact:+86-515-88334667/88203550
Address:Zhongshan 3rd Road, Coastal Chemical Industry Park, Yancheng, Jiangsu, China
Taizhou Chemedir Biopharm-tech Co., Ltd
Contact:+86 523 86200218
Address:G09, No. 1 Avenue China Medical City, Taizhou,Jiangsu, China
ShangHai Ruiyi Medical Technology Co.,Ltd.
Contact:+86-21-54718086
Address:No951 Jianchuan RD,Minhang District
Doi:10.1016/0040-4020(96)00200-1
(1996)Doi:10.1016/0008-6215(95)00379-7
(1996)Doi:10.1080/07328309608005696
(1996)Doi:10.1080/00397911.2011.558665
(2012)Doi:10.1016/0022-328X(95)05933-G
(1996)Doi:10.1016/S0040-4020(96)00931-3
(1996)